Zymeworks names Paul Moore as chief scientific officer

Canadian clinical-stage biotech Zymeworks (NYSE: ZYME) today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, as chief scientific officer, reporting directly to the chief executive Officer.

Dr Moore brings more than 25 years of USA-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of Food and Drug Administration-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. Dr Moore’s anticipated start date is July 18, 2022.

“Paul brings extensive experience in pre-clinical, translational and early clinical development of novel biologic-based therapeutics, and we are excited that he is joining Zymeworks in this key role at such an important stage of our company’s growth,” said Kenneth Galbraith, chairman and CEO of Zymeworks. “Since becoming CEO in early 2022, I have watched the world-class scientists in our Early Research and Development group make considerable progress in advancing our next generation of potential clinical candidates with the current objective of two new IND (Investigational New Drug) filings by 2024. With zanidatamab and ZW49 progressing rapidly through clinical development, Paul will be instrumental in driving our scientific vision and determining our future product pipeline development strategy as the leader of our renewed Early Research and Development Group,” he added.